Agios Pharmaceuticals Inc (AGIO)
33.03
+0.09
(+0.27%)
USD |
NASDAQ |
May 10, 16:00
33.03
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Cash and Short Term Investments (Quarterly): 597.99M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 597.99M |
December 31, 2023 | 776.93M |
September 30, 2023 | 647.49M |
June 30, 2023 | 702.57M |
March 31, 2023 | 739.20M |
December 31, 2022 | 783.12M |
September 30, 2022 | 727.68M |
June 30, 2022 | 819.31M |
March 31, 2022 | 923.53M |
December 31, 2021 | 1.020B |
September 30, 2021 | 1.266B |
June 30, 2021 | 1.673B |
March 31, 2021 | 2.336B |
December 31, 2020 | 572.93M |
September 30, 2020 | 605.54M |
June 30, 2020 | 790.13M |
March 31, 2020 | 528.62M |
December 31, 2019 | 564.88M |
September 30, 2019 | 451.90M |
June 30, 2019 | 495.39M |
March 31, 2019 | 524.56M |
December 31, 2018 | 585.30M |
September 30, 2018 | 669.89M |
Date | Value |
---|---|
June 30, 2018 | 716.90M |
March 31, 2018 | 782.45M |
December 31, 2017 | 423.94M |
September 30, 2017 | 507.93M |
June 30, 2017 | 586.04M |
March 31, 2017 | 479.76M |
December 31, 2016 | 541.31M |
September 30, 2016 | 579.10M |
June 30, 2016 | 465.37M |
March 31, 2016 | 312.89M |
December 31, 2015 | 317.00M |
September 30, 2015 | 352.36M |
June 30, 2015 | 369.79M |
March 31, 2015 | 344.71M |
December 31, 2014 | 342.06M |
September 30, 2014 | 219.97M |
June 30, 2014 | 238.48M |
March 31, 2014 | 162.27M |
December 31, 2013 | 166.77M |
September 30, 2013 | 194.96M |
June 30, 2013 | 99.28M |
March 31, 2013 | 115.75M |
December 31, 2012 | 127.98M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
451.90M
Minimum
Sep 2019
2.336B
Maximum
Mar 2021
851.09M
Average
733.44M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
Alnylam Pharmaceuticals Inc | 2.371B |
Amgen Inc | 9.708B |
Blueprint Medicines Corp | 647.90M |
Corcept Therapeutics Inc | 410.76M |
Ionis Pharmaceuticals Inc | 2.206B |